Documents obtained under Freedom of Information, suggest the US Government will share in the increased revenue pharmas generate by lifting drug prices outside the US, with President Donald Trump also giving his 'blessing' to companies that totally deny medicines to other countries to comply with his MFN policy
CEO confirms plans to engage further with government and relevant stakeholders post launch, to assess the appropriate timing and pathway to a PBS listing
With its competitor being deregistered at the end of 2024, Takeda has stepped in with the only vaccine of its kind Australia for a disease with more than 2600 cases a year
The TGA has finally given the greenlight to a drug that was lodged with the regulator in 2021, with the sponsor actively pursuing reimbursement via MSAC and the PBS
A change of headquarters to a brand new office space is planned to increase collaboration between teams
Voting opens today to fill vacancies on the Medicines Australia board with three leaders putting their hand up for two positions.
This high-flyer shot four places up the list to be named the third most powerful person in Australia this year - with PBS performance named as a reason for his success
In one of the most competitive markets in the world, this company is looking to reinvent the space, and its latest topline trial results have impressed
New research shows almost 50 per cent of PBS prescriptions are for conditions covered by additional training being undertaken by prescribing pharmacists
This company is downsizing its office space following the latest restructuring in Australia, with an official move slated for the start of next month
A Sydney-based pharma is up for sale, with almost the entire workforce wiped out, following the appointment of a Voluntary Administrator
The shortest line yet between America's MFN policy and a life-saving drug not being PBS listed has been drawn, with a company decrying the PBAC's unwillingness to adapt to a changed pricing environment
Three years after Australia's world-first decision to permit the prescribing of psilocybin and MDMA, the sector is booming and Big Pharma's are making a play
The Chief Scientific Officer for the NHS will visit Australia next month with a packed schedule including an address to the National Press Club
New approvals pathway could put the country at risk of contravening an international trade agreement, according to lawyers
Faced with growing challenges to listing some drugs on the PBS, Lilly has launched a platform to facilitate dispensing and delivery of medications to a patient's door at more affordable prices
While manufacturing costs have gone up, reimbursement is less than half what it was when this drug was first listed but the PBAC still said 'No' to a price rise. Now plans to delist it from the PBS have been delayed by six months following a patient outcry
Another impressive trial win for Summit Therapeutics' challenger to the world's biggest drug has been branded a good omen for Big Pharmas in the same space
Nine pharmas hope to add new labels to their drugs in Australia in 2027 after the TGA accepted their applications for evaluation between June and July
There has a been a rush on senior leadership moves across industry with a string of departures, returns, company moves and internal promotions
Future mega revenue earners unveiled alongside topline results for its next star performer, which beat a rival Lilly drug in a head-to-head trial
Australia's medicines regulator has accepted an additional 10 Type A applications between June and July, with some pegged blockbusters making the list
This member-led organisation has appointed the first female CEO in its 115-year history, following a national recruitment drive
